Privium Fund Management’s Clarus Therapeutics Holdings, Inc. Warrants CRXTW Stock Holding History

Privium Fund Management’s Portfolio CRXTW Stock Details CRXTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-163,030	Closed	-$13K	–	287
2022 Q2	$13K	Buy	+163,030	New	+$16K	﹤0.01%	162
2022 Q1	–	Sell	-163,030	Closed	-$42K	–	308
2021 Q4	$42K	Buy	+163,030	New	+$83.3K	0.01%	151

Other funds holding CRXTW

MSU

Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return

Privium Fund Management's CRXTW Position: Q3 2022 in Review

Privium Fund Management sold out of Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) in Q3 2022, closing a stake of 163,030 shares — an estimated $13K sold.

Privium Fund Management first reported a position in CRXTW in Q4 2021 and held it in 2 quarters. The position peaked at $42K in Q4 2021. 5 funds tracked by Wall St. Rank hold CRXTW as of Q3 2022.

Privium Fund Management reported no remaining Clarus Therapeutics Holdings, Inc. Warrants position as of Q3 2022 after selling out during the quarter.
Privium Fund Management sold 163,030 Clarus Therapeutics Holdings, Inc. Warrants shares in Q3 2022, an estimated $13K.
Privium Fund Management first reported a position in Clarus Therapeutics Holdings, Inc. Warrants in Q4 2021 and held it in 2 quarters.
Privium Fund Management's Clarus Therapeutics Holdings, Inc. Warrants position peaked at $42K in Q4 2021.
5 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Warrants as of Q3 2022.

Based on Privium Fund Management's 13F filing for Q3 2022, filed 3 Nov 2022.